Breast cancer is the most frequently diagnosed cancer in women, with more than 1.6 million new diagnoses around the world every year. Most of the new diagnoses are early stage, hormone receptor-positive breast cancers and can be effectively treated. 

In fact, it is estimated that approximately 70% of all early stage breast cancers do not require chemotherapy, but because it is difficult to distinguish which women are at a higher risk of their cancer progressing, the majority of women are prescribed aggressive chemotherapy but actually do not benefit from it. This unnecessarily exposes them to severe side effects and a poor quality of life.
OncoMark are currently developing the most accurate prognostic assay for breast cancer, which will help doctors and patients to confidently decide on the best course of treatment. 

This assay, named OncoMasTR, works by measuring the expression of specific genes in breast cancer tissue, and rapidly generates a result that clinicians and their patients can use to decide if chemotherapy is necessary.   

OncoMasTR will ensure that patients who do not require chemotherapy will avoid the harsh treatments and side effects.